Customer Service 1 (888) 261-2693
Please enter Search keyword. Advanced Search
Home About Us Resources Archive Free Reports Market Window

Double Your Returns with Some of the World's Best Companies

By Brett Eversole
Monday, January 7, 2013

While 2013 could easily be another great year for U.S. blue-chip stocks... I believe much bigger stock market gains are possible in a place where nobody else is buying right now...
 
I'm talking about Europe...
 
While U.S. blue-chip stocks are reasonably cheap, European blue-chip companies are cheaper in every way.
 
I know what you're thinking... Europe is a mess. Its countries are debt-laden. And the overall economy is bordering on recession. Nothing good happens in Europe, right? 
 
That's what the headlines say. And that's what created our incredible opportunity last year...  
 
The U.S. Dow Industrials Index returned double digits in 2012. But European blue chips more than doubled that return. And they're set to double it again this year.  
 
Last April, I showed readers how cheap a few of Europe's household names had gotten. Big oil company Total was trading at 6.8 times forward earnings... and yielding a huge 6%. Drugmaker Sanofi was nearly as cheap... so was manufacturing giant Siemens... communications company Telefonica... and more.  
 
The "Dow Jones Industrials of Europe" is the Stoxx 50 Index. At the time, the whole index of blue chips was yielding an incredible 5.2%. Excluding the financial crisis, European stocks are coming off their highest dividend yields in nearly 20 years.  
 
Since then, the Stoxx 50 is up 20.5% (including dividends). The Dow Jones Industrial Average is up just 6.7% over the same period.  
 
After this big outperformance, you might expect European blue-chips to underperform the U.S. But I expect the opposite for one simple reason... European companies are still dirt-cheap compared to the U.S.
 
The table below clearly shows it. Take a look... 
 
Relative Value in Europe 
 
2013 P/E 
P/B 
P/S 
Div. Yield 
Europe (Euro Stoxx 50) 
9.8 
1.1 
0.7 
4.3% 
U.S. (Dow Jones Ind.) 
11.1 
2.4 
1.2 
2.7% 
Europe Discount 
12% 
52% 
38% 
36% 
Data source: Bloomberg 
 
As you can see, European blue chips are cheaper than their U.S. counterparts in every way. To match the price-to-book ratio of U.S. blue chips, European blue chips would have to more than double! 
 
Now, I don't expect a quick double in European stocks. I think a better way to get a gauge of what to expect in 2013 is to look at earnings...
 
Analysts figure the U.S. Dow Jones Industrial Average will increase earnings 9% over 2012... and the Euro Stoxx 50 Index will increase earnings 11%.
 
Stocks to tend to rise as earnings grow. If earnings grow 11%, the Stoxx 50 will also have to increase 11% to maintain its current P/E ratio. I believe that will happen. I also believe the Stoxx 50 will close at least half the valuation gap between it and the U.S. Dow (currently a 12% discount).  
 
If that happens, we're looking at a potential 18.3% gain this year. If the Euro Stoxx 50 closes the entire discount, our upside is 25.9%.
 
Of course, earnings could disappoint. And outside events could cause valuations to fall. But that doesn't change the simple fact...
 
If you want to own blue-chip businesses this year, the best value around is in Europe.
 
You can easily make the trade with the SPDR Euro Stoxx 50 Fund (NYSEARCA: FEZ). This fund perfectly tracks the Euro Stoxx 50.
 
European blue chips crushed their U.S. counterparts in 2012, more than doubling their total return. And I believe we're set up to see the same thing happen in 2013.
 
If I'm right, safe 18%-26% returns are possible this year. Don't miss out.
 
Good investing, 
 
Brett Eversole




Further Reading:

One investment guru was buying European stocks last year. "But wait a minute... Isn't Greece about to explode? Isn't Spain next? Isn't the very existence of the euro in doubt?" Steve writes. "Yes, yes, and yes." But this is the type of situation that contrarian investors look for. Read more here: Why the "Gloom and Doom" Man Is Actually BUYING European Stocks.
 
Last April, Brett Eversole explained the deals being offered in European blue-chip stocks. Readers who took his advice and waited for the uptrend to appear are up 40%. Read more here: The World's Best Companies Want to Pay You Big Investment Income.

Market Notes


NEW HIGHS OF NOTE LAST WEEK 
 
Comcast (CMCSA)... cable company 
Expedia (EXPE)... online travel 
eBay (EBAY)... online auctions
Yahoo (YHOO)... search engine
Oracle (ORCL)... software 
Adobe Systems (ADBE)... software 
News Corp (NWS)... media 
Sirius XM Radio (SIRI)... satellite radio 
Alico (ALCO)... Florida real estate 
Boeing (BA)... aerospace 
Delta Air Lines (DAL)... airline 
CVS Caremark (CVS)... drug store 
Walgreens (WAG)... drug store
Citigroup (C)... bank 
Bank of America (BAC)... bank
Huntsman (HUN)... chemicals 
3M (MMM)... manufacturing
Monsanto (MON)... agriculture
Berkshire Hathaway (BRK)... Warren Buffett holding company 
iShares U.S. Home Construction Fund (ITB)... homebuilders 
Cheniere Energy (LNG)... liquefied natural gas 
Union Pacific (UNP)... railroads 
Constellation Brands (STZ)... booze 

NEW LOWS OF NOTE LAST WEEK 
 
U.S. Natural Gas Fund (UNG)... "world's worst investment" candidate
Dollar General (DG)... discount retailer
Kohl's (KSS)... clothes

premium teaser

Triple-digit upside in this European opportunity today...
 
This is exactly the kind of set-up we dream of: super-cheap values... in a market where nobody is interested... and a solid uptrend is in place.
 

In The Daily Crux



Recent Articles
Legal Notices: Stansberry Research LLC (Stansberry Research) is a publishing company and the indicators, strategies, reports, articles and all other features of our products are provided for informational and educational purposes only and should not be construed as personalized investment advice. Our recommendations and analysis are based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.

 

Readers should be aware that trading stocks and all other financial instruments involves risk. Past performance is no guarantee of future results, and we make no representation that any customer will or is likely to achieve similar results.

 

Our testimonials are the words of real subscribers received in real letters, emails, and other feedback who have not been paid for their testimonials. Testimonials are printed under aliases to protect privacy, and edited for length. Their claims have not been independently verified or audited for accuracy. We do not know how much money was risked, what portion of their total portfolio was allocated, or how long they owned the security. We do not claim that the results experienced by such subscribers are typical and you will likely have different results.

 

Any performance results of our recommendations prepared by Stansberry Research are not based on actual trading of securities but are instead based on a hypothetical trading account. Hypothetical performance results have many inherent limitations. Your actual results may vary.

 

Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies), employees, and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

 

© 2024 Stansberry Research, LLC. | Privacy Policy| Customer Service
Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC. 1125 N Charles St. Suite 500, Baltimore MD 21202.